The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression
Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Kankana Bardhan(Seres Therapeutics (United States)), Álvaro Torres-Gómez(Research Institute Hospital 12 de Octubre), Lequn Li(Beth Israel Deaconess Medical Center), Jessica D. Weaver(Beth Israel Deaconess Medical Center), Esther M. Lafuente(Universidad Complutense de Madrid), Laura Strauss(AVEO Oncology (United States)), Duygu Sari(Sağlık Bilimleri Üniversitesi)
Cited by 29
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859